306 related articles for article (PubMed ID: 11989608)
1. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C
Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
[No Abstract] [Full Text] [Related]
2. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
O'Dwyer ME; Druker BJ
Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
[TBL] [Abstract][Full Text] [Related]
3. Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME; Druker BJ
J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
[TBL] [Abstract][Full Text] [Related]
4. STI571 (Gleevec) as a paradigm for cancer therapy.
Druker BJ
Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
6. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
7. [New molecular therapy options in hematology and oncology, exemplified by STI571].
Schleuning M; Hiddemann W
Internist (Berl); 2001 Dec; 42(12):1591-7. PubMed ID: 11793598
[No Abstract] [Full Text] [Related]
8. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
Druker BJ
J Natl Cancer Inst; 2002 Nov; 94(22):1660-1. PubMed ID: 12441314
[No Abstract] [Full Text] [Related]
9. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
10. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
Mauro MJ; O'Dwyer ME; Druker BJ
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S77-8. PubMed ID: 11587372
[TBL] [Abstract][Full Text] [Related]
11. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Sausville EA
J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
[No Abstract] [Full Text] [Related]
12. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
13. STI571: a magic bullet?
Verweij J; Judson I; van Oosterom A
Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
[No Abstract] [Full Text] [Related]
14. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.
O'Dwyer ME; Druker BJ
Curr Cancer Drug Targets; 2001 May; 1(1):49-57. PubMed ID: 12188891
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on the development of a molecularly targeted agent.
Druker BJ
Cancer Cell; 2002 Feb; 1(1):31-6. PubMed ID: 12086885
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
17. Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
Sausville EA
J Natl Cancer Inst; 2000 Oct; 92(20):1626-7. PubMed ID: 11036101
[No Abstract] [Full Text] [Related]
18. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.
La Rosée P; O'Dwyer ME; Druker BJ
Leukemia; 2002 Jul; 16(7):1213-9. PubMed ID: 12094245
[TBL] [Abstract][Full Text] [Related]
19. [How I treat...chronic myeloid leukemia].
Hafraoui K; Humblet-Baron S; Baron F; Beguin Y; Fillet G
Rev Med Liege; 2003 Jan; 58(1):7-12. PubMed ID: 12647591
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
Nadal E; Olavarria E
Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]